Notably, bioluminescence imaging revealed a significant reduction in tumour volume after anti-PD-1 plus anti-TIGIT antibody treatment on Day 21 and Day 30 compared to the controls treated with PBS (Fig. 2e). The gene discussed is PDCD1; the disease is neoplasm.